ym 529 has been researched along with Multiple Myeloma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iguchi, T; Ikeda, Y; Kizaki, M; Miyakawa, Y; Yamamoto, K | 1 |
| Fujiwara, K; Ito, T; Kato, C; Kusunoki, T; Nishida, S; Nishinobo, M; Ogaki, M; Satou, T; Tsubaki, M; Yamazoe, Y | 1 |
| Ashihara, E; Hatsuse, M; Hirai, H; Inaba, T; Nakagawa, M; Okamoto, A; Okano, A; Shimazaki, C; Takahashi, R | 1 |
| Otsuki, T; Sugihara, T; Wada, H; Yamada, O; Yata, K; Yawata, Y | 1 |
4 other study(ies) available for ym 529 and Multiple Myeloma
| Article | Year |
|---|---|
Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway.
Topics: Apoptosis; Cell Division; Cell Line, Tumor; Checkpoint Kinase 1; Diphosphonates; Diterpenes; Enzyme Inhibitors; Farnesol; Humans; Imidazoles; Interleukin-6; MAP Kinase Signaling System; Mevalonic Acid; Multiple Myeloma; Phosphorylation; Protein Kinases; S Phase; Signal Transduction; Stromal Cells | 2003 |
Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits macrophage inflammatory protein 1 alpha expression and secretion in mouse myeloma cells.
Topics: Animals; Butadienes; Cell Growth Processes; Cell Line, Tumor; Chemokine CCL3; Chromones; Diphosphonates; I-kappa B Proteins; Imidazoles; Lipopolysaccharides; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Morpholines; Multiple Myeloma; Nitriles; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Polyisoprenyl Phosphates; Proto-Oncogene Proteins c-akt; RNA, Messenger; Sesquiterpenes | 2008 |
A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Division; Diphosphonates; Flow Cytometry; Humans; Imidazoles; Multiple Myeloma; Pamidronate; Tumor Cells, Cultured | 2001 |
Synergistic growth inhibition of YM529 with biologic response modifiers (BRMs) in myeloma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Diphosphonates; Drug Synergism; Humans; Imidazoles; Interferon-alpha; Interphase; Multiple Myeloma; RNA; Thalidomide; Tretinoin; Tumor Cells, Cultured | 2002 |